𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CONTINUOUS AND GROUP SEQUENTIAL CONDITIONAL PROBABILITY RATIO TESTS FOR PHASE II CLINICAL TRIALS

✍ Scribed by MING TAN; XIAOPING XIONG


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
1020 KB
Volume
15
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

✦ Synopsis


We present continuous and group sequential designs for phase I1 clinical trials based on the sequential conditional probability ratio test (SCPRT). The SCPRT is derived from a conditional likelihood ratio, where the conditioning is on what the corresponding (reference) fixed sample size test (RFSST) would achieve. In other words, we obtain the sequential design by controlling the maximum probability that the SCPRT does not agree with the RFSST. We shall discuss the difference between SCPRT and stochastic curtailment which also uses the concept of conditional distribution. We show that the power function of the SCPRT is virtually the same as that of the RFSST and its average sample numbers (ASNs) are close to those of Wald's sequential probability ratio test (SPRT), whereas its maximum sample size is no greater than that of the RFSST. Thus the SCPRT has all the desirable properties, such as allowing the use of the RFSST at the last analysis, of the Fleming procedure for phase I1 trials. The SCPRT, however, preserves the power function of the RFSST better and gives us the option for continuous monitoring. Our recommendation, therefore, is to use a group SCPRT boundary (for interim analyses performed as scheduled) embedded in a continuous SCPRT boundary (for unplanned interim analyses and analyses at times based on data trends). We provide as well a bias-adjusted estimator of the success rate after sequential stopping. We illustrate the method with several examples. The method applies to any single-arm clinical trial with binary endpoints, such as the classic paired design.


πŸ“œ SIMILAR VOLUMES


A Microcomputer Program for the Design a
✍ E. Bellissant; J. Benichou; Cl. Chastang πŸ“‚ Article πŸ“… 1994 πŸ› Elsevier Science 🌐 English βš– 470 KB

We developed an interactive and menu-driven computer program to help investigators design and analyze phase II cancer clinical trials with a group sequential method, namely the sequential probability ratio test or the triangular test. Based on the values selected for the parameters of the trial, the

Sequential dose-dense doxorubicin and if
✍ Joan Maurel; JoaquΓ­n Fra; Antonio LΓ³pez-Pousa; Xavier GarcΓ­a del Muro; Carmen Ba πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Combinations of high‐dose ifosfamide (IF; 10–12 g/m^2^) plus doxorubicin (DX; 50–90 mg/m^2^) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy. Although these combination regimens appear to yield high

Edatrexate (10-ethyl-deaza-aminopterin)
✍ Hedy L. Kindler; Chandra P. Belani; James E. Herndon II; Nicholas J. Vogelzang; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 1 views

The Cancer and Leukemia Group B (CALGB) conducted sequential Phase II multicenter trials to evaluate the activity of edatrexate alone (E) or with leucovorin rescue (EL) in patients with malignant pleural mesothelioma (CALGB Protocol 9131).

The combination of cisplatin, doxorubici
✍ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 482 KB πŸ‘ 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat